MX2020001874A - Formulaciones farmacéuticas sólidas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico y la adenomiosis. - Google Patents

Formulaciones farmacéuticas sólidas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico y la adenomiosis.

Info

Publication number
MX2020001874A
MX2020001874A MX2020001874A MX2020001874A MX2020001874A MX 2020001874 A MX2020001874 A MX 2020001874A MX 2020001874 A MX2020001874 A MX 2020001874A MX 2020001874 A MX2020001874 A MX 2020001874A MX 2020001874 A MX2020001874 A MX 2020001874A
Authority
MX
Mexico
Prior art keywords
adenomyosis
pharmaceutical formulations
solid pharmaceutical
polycystic ovary
ovary syndrome
Prior art date
Application number
MX2020001874A
Other languages
English (en)
Inventor
Yuchuan Gong
Alexander RUGGLES
Kristof Chwalisz
James W Thomas
Jane Castelli-Haley
Keith Gordon
Michael C Snabes
Ahmed M Soliman
Oscar Antunez Flores
Rita Jain
Janine D North
Hannah Palac
Paul M Peloso
Yihong Qiu
Jared A Baird
Charlotte D Owens
Juki Wing- Keung NG
Yuerong Hu
hui Zu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/043321 external-priority patent/WO2019203870A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from PCT/US2018/047073 external-priority patent/WO2019036713A1/en
Publication of MX2020001874A publication Critical patent/MX2020001874A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

La presente divulgación se refiere a composiciones farmacéuticas que comprenden un antagonista de la hormona liberadora de gonadotropina (GnRH) y a métodos para preparar y usar tales composiciones. La divulgación también se refiere a métodos para facilitar la liberación de un antagonista de GnRH desde una composición farmacéutica.
MX2020001874A 2017-08-18 2018-08-20 Formulaciones farmacéuticas sólidas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico y la adenomiosis. MX2020001874A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762547410P 2017-08-18 2017-08-18
US201862660104P 2018-04-19 2018-04-19
PCT/US2018/043321 WO2019203870A1 (en) 2018-04-19 2018-07-23 Methods of treating heavy menstrual bleeding
PCT/US2018/047073 WO2019036713A1 (en) 2017-08-18 2018-08-20 SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS

Publications (1)

Publication Number Publication Date
MX2020001874A true MX2020001874A (es) 2020-09-14

Family

ID=69636712

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001874A MX2020001874A (es) 2017-08-18 2018-08-20 Formulaciones farmacéuticas sólidas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico y la adenomiosis.
MX2023002449A MX2023002449A (es) 2017-08-18 2020-02-17 Formulaciones farmaceuticas solidas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico y la adenomiosis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002449A MX2023002449A (es) 2017-08-18 2020-02-17 Formulaciones farmaceuticas solidas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico y la adenomiosis.

Country Status (10)

Country Link
EP (1) EP3668514A4 (es)
JP (1) JP7350715B2 (es)
KR (1) KR20200053502A (es)
CN (1) CN111246850A (es)
AU (1) AU2018317473A1 (es)
BR (1) BR112020003388A2 (es)
CA (1) CA3073247A1 (es)
IL (1) IL272682A (es)
MX (2) MX2020001874A (es)
SG (1) SG11202001439QA (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112494425B (zh) * 2020-12-14 2023-06-23 珠海优润医药科技有限公司 一种恶拉戈利钠口服溶液及其制备方法
CN117545484A (zh) * 2021-04-21 2024-02-09 上海启晟合研医药科技有限公司 一种噁拉戈利钠组合物
CN113876728B (zh) * 2021-11-17 2022-12-13 南京唯创远医药科技有限公司 一种噁拉戈利冻干片及其制备方法
CN114948889A (zh) * 2022-06-17 2022-08-30 哈药集团技术中心 一种噁拉戈利片的制备方法及其制备的噁拉戈利片
CN115804774A (zh) * 2022-08-26 2023-03-17 济川(上海)医学科技有限公司 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
CN116459225B (zh) * 2023-04-26 2023-11-10 东莞市金美济药业有限公司 一种艾拉戈克钠片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
WO2009062087A1 (en) 2007-11-07 2009-05-14 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
KR20110007242A (ko) 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
CN206120770U (zh) * 2015-06-03 2017-04-26 南京三迭纪医药科技有限公司 药品剂型
US20190321363A1 (en) * 2016-06-20 2019-10-24 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
WO2018224063A2 (en) * 2017-06-08 2018-12-13 Zentiva, K.S. Solid forms of elagolix

Also Published As

Publication number Publication date
EP3668514A1 (en) 2020-06-24
IL272682A (en) 2020-03-31
SG11202001439QA (en) 2020-03-30
JP2020531475A (ja) 2020-11-05
JP7350715B2 (ja) 2023-09-26
CA3073247A1 (en) 2019-02-21
EP3668514A4 (en) 2021-07-14
AU2018317473A1 (en) 2020-03-05
MX2023002449A (es) 2023-03-22
BR112020003388A2 (pt) 2020-08-25
CN111246850A (zh) 2020-06-05
KR20200053502A (ko) 2020-05-18

Similar Documents

Publication Publication Date Title
MX2023002450A (es) Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.
MX2023002449A (es) Formulaciones farmaceuticas solidas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico y la adenomiosis.
MX2020005462A (es) Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2020005622A (es) Compuestos de indol sustituidos con arilo y heteroarilo.
MX2020005513A (es) Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
MX2022003967A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MX2020005873A (es) Compuestos de 6-azaindol.
MX2020006168A (es) Compuestos de 4-azaindol.
JOP20180092A1 (ar) مثبطات hiv بروتياز
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2020006014A (es) Compuestos de diazaindol.
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX2020006093A (es) Compuestos de indol eter sustituidos.
MX2015016825A (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculos y sus usos.
MX2018015247A (es) Heterociclos de biarilmetilo.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
ZA202002852B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
MX2022006823A (es) Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos.
MX2019003093A (es) Formas cristalinas.
MX2018005134A (es) Formulacion de factor viii (fviii).
MX2018000746A (es) Composiciones farmaceuticas solidas para el tratamiento del vhc.
MX2019003815A (es) Composiciones farmaceuticas de antagonista del 5-ht6.
MX2017016108A (es) Capsulas de capecitabina de liberacion prolongada.
PH12019501689A1 (en) Composition comprising immediate release and extended release capecitabine